Business
Product Launch
Product Launch.
About this update from Ixico Plc
[{"type":"text","content":"\n RNS Number : 4073W Phytopharm PLC 11 June 2008 \n \n11 June 2008\n\nPhytopharm plc\n\nLaunch of Phytopica® in Hong Kong\n\n\nGODMANCHESTER, Cambridgeshire, U.K. (11 June 2008) - Phytopharm plc (PYM: London Stock Exchange) ('Phytopharm' or the 'Company') announces today the launch of Phytopica® in Hong Kong by its partner, Intervet/Schering-Plough Animal Health.\n\nIn January 2006, Phytopharm entered into an exclusive global agreement with Schering-Plough Animal Health for the Company's canine skin health product, Phytopica®. Under the terms of the agreement, Phytopharm is responsible for manufacturing Phytopica® whilst Schering-Plough Animal Health is responsible for the global sales, marketing and distribution of Phytopica®. In April 2006, Schering-Plough Animal Health launched Phytopica® in the UK followed by launches in Italy and France in March and April 2007. The product has enjoyed firm support from veterinary dermatologists and recorded strong sales growth.\n\nPhytopica® is effective in the management of canine skin health by providing a novel 3 in 1 approach to help maintain a normal healthy immune system, support normal white cell function and provide anti-oxidant benefits. The beneficial effects and excellent safety profile of Phytopica® have been proven extensively in clinical trials and the product has been found to be suitable for all dogs whatever size or breed. \n\nIn November 2007, Schering-Plough completed the acquisition of Organon BioSciences N.V which included the animal health business, Intervet. The enlarged animal health business is now operating as Intervet/Schering-Plough Animal Health. Following the Hong Kong launch, Intervet/Schering-Plough Animal Health will seek to market and distribute Phytopica® in further countries.\n\nCanine dermatological disorders are recognised by veterinarians to be a major problem in small animal practice, with an estimated 15-30% of the global dog population affected by skin conditions (Muller & Kirk's Small Animal Dermatology, 6th Ed, 2000).\n\nCommenting on today's announcement, Dr Daryl Rees, Chief Executive Officer of Phytopharm, said: 'We are delighted with the launch of Phytopica® in Ho...